Interestingly, although IDO1 expression is commonly associated with immunosuppression and tumor invasion, IDO1 is associated with improved therapeutic response in NSCLC treated with PD‐L1 blockade,108 which is not observed in conventional chemotherapy. Here, IDO1 is linked to non-small cell lung carcinoma.